Recent Updates
Recently added Catalysts

Cenderitide

Phase 2

Heart Failure | Small molecule | Cardiovascular |Capricor Therapeutics, Inc.|Last Updated: Feb 10, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials2
Total Enrollment22
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02359227Safety Study of Cenderitide in Stable Chronic Heart FailurePHASE2 COMPLETED 14Jan 1, 2015Apr 1, 2015Feb 10, 2020 -
NCT02603614Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal ImpairmentPHASE1/PHASE2 COMPLETED 8Dec 1, 2015Mar 1, 2016Feb 10, 2020 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
CenderitideDRUGCenderitide is a dual receptor natriuretic peptide.
PlaceboDRUGPlacebo control
Unlock Study Design Details